STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNN
  4. [6-K] SMITH & NEPHEW PLC Current Report (Foreign Issuer)

Smith+Nephew (NYSE: SNN) schedules Q1 2026 trading report and analyst call

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Smith+Nephew, a global medical technology company, has filed a report to confirm the timing of its first quarter 2026 trading update. The company will publish its trading report for the quarter ended 28 March 2026 on 6 May 2026 at 7:00am BST / 2:00am EDT, followed by an analyst conference call at 8:30am BST / 3:30am EDT.

Smith+Nephew focuses on the repair, regeneration and replacement of soft and hard tissue through three business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It operates in more than 100 countries and generated $6.2 billion of annual sales in 2025.

Positive

  • None.

Negative

  • None.
Annual sales $6.2 billion Full year 2025
Employees 17,000 employees Global workforce
Q1 2026 quarter end 28 March 2026 Quarter covered by trading report
Trading report release time 7:00am BST / 2:00am EDT Publication time on 6 May 2026
Analyst call time 8:30am BST / 3:30am EDT Conference call on 6 May 2026
trading report financial
"will announce its trading report for the first quarter ended 28 March 2026"
medical technology financial
"Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company"
forward-looking statements regulatory
"This document may contain forward-looking statements that may or may not prove accurate"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
reimbursement decisions regulatory
"regulatory approvals, reimbursement decisions or other government actions"
Advanced Wound Management financial
"our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management"
Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
 
April 22, 2026
 
Commission File Number 001-14978
 
SMITH & NEPHEW plc
(Registrant’s name)
 
Building 5, Croxley Park, Hatters Lane
Watford, England, WD18 8YE
 (Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F  ✔         Form 40-F __
 
 
 
 
 
Timing of Smith+Nephew First Quarter 2026 Trading Report
 
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, will announce its trading report for the first quarter ended 28 March 2026 on Wednesday 6 May 2026 at 7.00am BST / 2.00am EDT. This will be followed by a conference call for financial analysts at 8.30am BST / 3.30am EDT, details of which will be published on the Smith+Nephew website at: https://www.smith-nephew.com/en/who-we-are/investors

Enquiries

Investors/ Analysts
 
Emily Heaven                                                                  +44 (0) 1923 477433
 
Craig Bijou                                                                      +1 (475) 850 8282
 
Smith+Nephew
 
Media
 
Charles Reynolds                                                            +44 (0) 1923 477314
 
Smith+Nephew
 
LEI: 213800ZTMDN8S67S1H61

About Smith+Nephew
 
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
​
Founded in Hull, UK, in 1856, we now operate in more than 100 countries and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
 
​For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
 
Forward-looking Statements
 
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
 
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
 
 
 
Smith & Nephew plc
 
 
(Registrant)
 
 
 
 
 
 
Date: April 22, 2026
By:
/s/ Helen Barraclough
 
 
Helen Barraclough
 
 
Company Secretary

Source: View Original Filing on SEC EDGAR

FAQ

When will Smith+Nephew (SNN) release its Q1 2026 trading report?

Smith+Nephew will release its first quarter 2026 trading report on 6 May 2026. The update covers the quarter ended 28 March 2026 and will be published at 7:00am BST / 2:00am EDT for investors and analysts.

Will Smith+Nephew (SNN) hold a call to discuss the Q1 2026 trading update?

Yes. Smith+Nephew will host a conference call for financial analysts on 6 May 2026 at 8:30am BST / 3:30am EDT. Access details will be provided on the company’s investor relations section of its website.

What kind of business is Smith+Nephew (SNN)?

Smith+Nephew is a global medical technology company focused on repairing, regenerating and replacing soft and hard tissue. It operates through Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, serving healthcare providers in more than 100 countries worldwide.

How large is Smith+Nephew’s (SNN) business based on recent sales?

Smith+Nephew generated annual sales of $6.2 billion in 2025. This figure reflects its global portfolio across orthopaedics, sports medicine, ENT and advanced wound care products, supported by its operations in over 100 countries.

How many people does Smith+Nephew (SNN) employ globally?

Smith+Nephew employs around 17,000 people worldwide. These employees support its medical technology portfolio and innovation activities across three main business units and more than 100 countries where the company operates.

On which indices and exchanges is Smith+Nephew listed?

Smith+Nephew is listed on the London Stock Exchange and the New York Stock Exchange. It is a constituent of the FTSE 100 index and trades under the ticker SNN on the NYSE, with a separate London listing.